- Home
- FBNC vs IBRX Comparison
FBNC vs IBRX Comparison
Compare FBNC & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBNC
- IBRX
- Stock Information
- Founded
- FBNC 1934
- IBRX 2014
- Country
- FBNC United States
- IBRX United States
- Employees
- FBNC N/A
- IBRX N/A
- Industry
- FBNC Major Banks
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FBNC Finance
- IBRX Health Care
- Exchange
- FBNC Nasdaq
- IBRX Nasdaq
- Market Cap
- FBNC 2.2B
- IBRX 2.3B
- IPO Year
- FBNC N/A
- IBRX N/A
- Fundamental
- Price
- FBNC $48.95
- IBRX $2.20
- Analyst Decision
- FBNC Buy
- IBRX Strong Buy
- Analyst Count
- FBNC 4
- IBRX 6
- Target Price
- FBNC $56.67
- IBRX $9.83
- AVG Volume (30 Days)
- FBNC 190.3K
- IBRX 8.8M
- Earning Date
- FBNC 10-22-2025
- IBRX 11-04-2025
- Dividend Yield
- FBNC 1.90%
- IBRX N/A
- EPS Growth
- FBNC N/A
- IBRX N/A
- EPS
- FBNC 2.39
- IBRX N/A
- Revenue
- FBNC $364,799,000.00
- IBRX $82,555,000.00
- Revenue This Year
- FBNC $40.17
- IBRX $629.94
- Revenue Next Year
- FBNC $12.16
- IBRX $109.91
- P/E Ratio
- FBNC $20.35
- IBRX N/A
- Revenue Growth
- FBNC 0.59
- IBRX 1025.95
- 52 Week Low
- FBNC $34.50
- IBRX $1.83
- 52 Week High
- FBNC $56.45
- IBRX $5.43
- Technical
- Relative Strength Index (RSI)
- FBNC 46.52
- IBRX 45.00
- Support Level
- FBNC $47.83
- IBRX $1.95
- Resistance Level
- FBNC $50.97
- IBRX $2.13
- Average True Range (ATR)
- FBNC 1.17
- IBRX 0.13
- MACD
- FBNC -0.04
- IBRX -0.00
- Stochastic Oscillator
- FBNC 37.96
- IBRX 44.32
About FBNC First Bancorp
First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing and investment advisory services.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.